montbretin A

a pancreatic alpha-amylase inhibitor isolated from Crocosmia crocosmiiflora; structure in first source

Networked: 6 relevant articles (2 outcomes, 0 trials/studies)

1.	Irmisch, Sandra: 3 articles (01/2021 - 01/2019)
2.	Jancsik, Sharon: 3 articles (01/2021 - 01/2019)
3.	Madilao, Lufiani L: 3 articles (01/2021 - 01/2019)
4.	Bohlmann, Joerg: 2 articles (01/2021 - 01/2019)
5.	Andersen, Raymond J: 2 articles (01/2016 - 09/2015)
6.	Brayer, Gary D: 2 articles (01/2016 - 09/2015)
7.	Coleman, John: 2 articles (01/2016 - 09/2015)
8.	McNeill, John H: 2 articles (01/2016 - 09/2015)
9.	Liu, Hannah L: 1 article (01/2021)
10.	Sunstrum, Frederick G: 1 article (01/2021)

1.	Obesity 01/01/2021 - "Montbretin A (MbA) is of particular interest as a novel therapeutic for type-2 diabetes and obesity. " 12/01/2019 - "The specialized metabolite montbretin A (MbA) is being developed for treatment of T2D and obesity due to its unique pharmacological activity as a highly effective and selective inhibitor of the human pancreatic α-amylase. " 09/01/2015 - "The complex plant flavonol glycoside montbretin A is a potent (Ki = 8 nM) and specific inhibitor of human pancreatic α-amylase with potential as a therapeutic for diabetes and obesity. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2019 - "The plant metabolite montbretin A (MbA) and its precursor mini-MbA are potential new drugs for treating type 2 diabetes. " 01/01/2023 - "In contrast to acarbose, montbretin A, a new drug candidate for the treatment of type 2 diabetes, has been reported to be more specific for the inhibition of α-amylase, notably human pancreatic α-amylase. " 01/01/2016 - "Zucker diabetic fatty rats, an animal model of type 2 diabetes, were treated with montbretin A (MbA), a selective human pancreatic α-amylase inhibitor, isolated from the corms of the Crocosmia crocosmiiflora plant that may have potential as a glucose-lowering agent. "